Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

被引：15
|
作者：
Kater, Arnon P. [1 ]
Christensen, Jacob Haaber [2 ]
Bentzen, Hans Herluf [3 ]
Niemann, Carsten Utoft [4 ]
Hutchings, Martin [4 ]
Chen, Jenny [5 ]
Rios, Marcia [6 ]
Palenski, Tammy [6 ]
Li, Tommy [5 ]
Mato, Anthony R. [7 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands
[2] Odense Univ Hosp, Odense, Denmark
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Copenhagen Univ Hosp, Rigshospitalet, Copenhagen, Denmark
[5] Genmab, Princeton, NJ USA
[6] AbbVie, N Chicago, IL USA
[7] Mem Sloan Kettering Canc Ctr, Chron Lymphocyt Leukemia Program, New York, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146563
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2627
引用
收藏
页数：4
相关论文
共 50 条
  • [31] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
    Falchi, Lorenzo
    Morschhauser, Franck
    Linton, Kim
    Huang, Huiqiang
    Galderisi, Faith
    Quadri, Syed
    Zeng, Lingmin
    Hoehn, Daniela
    Seymour, John F.
    BLOOD, 2023, 142
  • [32] Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
    Montillo, Marco
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Coscia, Marta
    Petrizzi, Valeria Belsito
    Orlandi, Ester
    Cascavilla, Nicola
    Ghia, Paolo
    Motta, Marina
    Gallamini, Andrea
    Frustaci, Anna Maria
    Rossi, Davide
    De Paoli, Lorenzo
    Nichelatti, Michele
    Morra, Enrica
    Massaia, Massimo
    HAEMATOLOGICA, 2014, 99 (09) : E159 - E161
  • [33] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [34] Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Wu, Jun
    Broberg, Per
    Buchbjerg, Jeppe
    Fukuhara, Noriko
    ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
  • [35] Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
    Falchi, Lorenzo
    Keating, Michael J.
    Badoux, Xavier C.
    Wierda, William G.
    O'Brien, Susan Mary
    Smith, Susan C.
    Wen, Sijin
    Kantarjian, Hagop
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients
    Ahmed, Tamer
    Hayslip, John
    Leggas, Markos
    CANCER RESEARCH, 2012, 72
  • [37] Characterization and predictors of sleep disturbance in patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
    Westbrook, Travis D.
    Maddocks, Kami J.
    Andersen, Barbara L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [39] NURSING IMPLICATIONS FOR VENETOCLAX USE IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MULTICENTER ANALYSIS
    Kennard, Kaitlin
    Howlett, Christina
    Timberg, Mary
    Staller, Emma
    Varga, Julia
    Dorsey, Colleen
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [40] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
12345